loading
전일 마감가:
$42.83
열려 있는:
$42.63
하루 거래량:
2.46M
Relative Volume:
0.88
시가총액:
$7.61B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-18.25
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-2.50%
1개월 성능:
+17.24%
6개월 성능:
+56.44%
1년 성능:
+75.96%
1일 변동 폭
Value
$42.28
$44.07
1주일 범위
Value
$41.80
$45.48
52주 변동 폭
Value
$21.72
$45.48

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
명칭
Bridgebio Pharma Inc
Name
전화
(650) 391-9740
Name
주소
3160 PORTER DR., PALO ALTO, CA
Name
직원
730
Name
트위터
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
BBIO's Discussions on Twitter

BBIO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BBIO
Bridgebio Pharma Inc
43.99 7.61B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-31 개시 Redburn Atlantic Buy
2024-10-16 개시 Scotiabank Sector Outperform
2024-10-03 개시 Oppenheimer Perform
2024-09-04 개시 Piper Sandler Overweight
2024-03-21 재개 Raymond James Outperform
2024-01-31 개시 BMO Capital Markets Market Perform
2023-12-08 개시 Wells Fargo Overweight
2023-11-07 개시 Citigroup Buy
2023-10-24 개시 Cantor Fitzgerald Overweight
2023-07-18 다운그레이드 Jefferies Buy → Hold
2023-04-19 개시 Evercore ISI Outperform
2023-02-06 개시 Cowen Outperform
2021-12-27 재확인 Mizuho Buy
2021-12-27 재확인 SVB Leerink Outperform
2021-09-10 업그레이드 BofA Securities Neutral → Buy
2021-05-21 개시 UBS Buy
2021-03-22 재확인 Goldman Buy
2021-02-22 재개 JP Morgan Overweight
2021-02-09 재개 Goldman Buy
2021-01-11 재확인 H.C. Wainwright Buy
2020-12-10 재확인 H.C. Wainwright Buy
2020-06-25 개시 BofA/Merrill Neutral
2020-05-19 개시 BTIG Research Buy
2020-04-13 개시 H.C. Wainwright Buy
2020-02-19 개시 Mizuho Buy
2019-07-26 개시 Raymond James Outperform
2019-07-22 개시 BMO Capital Markets Outperform
2019-07-22 개시 Goldman Buy
2019-07-22 개시 JP Morgan Overweight
2019-07-22 개시 Jefferies Buy
2019-07-22 개시 Piper Jaffray Overweight
2019-07-22 개시 SVB Leerink Outperform
모두보기

Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스

pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BBIO with Outperform Rating - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BBIO with Outperform Rating | BBIO Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

BridgeBio (BBIO) Gains Positive Outlook with Strong Transthyreti - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

BridgeBio (BBIO) Receives Outperform Rating from Wolfe Research | BBIO Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

BridgeBio Pharma stock reaches 52-week high at $40.45 By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

BridgeBio Pharma stock reaches 52-week high at $40.45 - Investing.com

Jun 16, 2025
pulisher
Jun 14, 2025

BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

BridgeBio Pharma’s SWOT analysis: stock poised for growth amid challenges - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

When the Price of (BBIO) Talks, People Listen - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Comments on BBIO FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Day 8 of Gains Streak for BridgeBio Pharma Stock with 21% Return (vs. 42% YTD) [6/9/2025] - Trefis

Jun 10, 2025
pulisher
Jun 09, 2025

BridgeBio stock holds Buy rating, price target at $56H.C. Wainwright - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwri - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwright & Co. | BBIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | BBIO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com

Jun 09, 2025
pulisher
Jun 07, 2025

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

BridgeBio Pharma stock hits 52-week high at $39.58 By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Piper Sandler maintains overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com UK

Jun 06, 2025
pulisher
Jun 05, 2025

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

BMO Capital raises BridgeBio Pharma stock price target to $42 By Investing.com - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exploring High Growth Tech Stocks In The US Market - simplywall.st

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 01, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 28, 2025
pulisher
May 27, 2025

Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st

May 27, 2025
pulisher
May 26, 2025

BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com

May 26, 2025
pulisher
May 24, 2025

Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 24, 2025
pulisher
May 21, 2025

The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan

May 20, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria

May 19, 2025

Bridgebio Pharma Inc (BBIO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Kumar Neil
Chief Executive Officer
Jul 01 '25
Sale
42.54
40,000
1,701,400
975,686
VIKING GLOBAL INVESTORS LP
10% Owner
Jun 27 '25
Sale
44.00
3,500,000
154,000,000
18,555,375
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
자본화:     |  볼륨(24시간):